Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Feb 15;10(3):152. doi: 10.1038/s41419-019-1403-x

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2019

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 1 — a The relative expression of BAP31 mRNA in CRC tissues of 57 cases compared to pericarcinous tissues as detected by real-time PCR (*P < 0.05). b, c The relative expression of BAP31 protein in CRC tissues compared to pericarcinous tissues as detected by immunohistochemistry (**P < 0.01; 1–6: six pairs of resected CRC specimens were randomly selected from stage II and stage III patients; samples 1–3 were in stage II, and samples 4–6 in stage III) and western blotting (**P < 0.01; N, pericarcinous tissues; C, colorectal cancer; 1–4: eight pairs of clinically resected CRC specimens randomly selected from stage II and stage III patients; samples 1–4 were in stage II, and samples 5–8 in stage III). d, e The relative expression of BAP31 protein in CRC tissues compared to pericarcinous tissues as detected by immunohistochemistry (scale bar, 50 μm; **P < 0.01). (f) The expression of BAP31 in CRC tissues of patients with different clinic stages: 1–3, stage I; 4–29, stage II; 30–50, stage III; 51–57, stage IV. CRC, colorectal cancer